Clinical Trial Update: Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tislelizumab plus a tyrosine kinase inhibitor as adjuvant therapy versus active surveillance in hepatocellular carcinoma aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TKI (tyrosine kinase inhibitor)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Beijing 302 Hospital | Conditions: Liver Neoplasms | Phase 2 | Status: UNKNOWN